NEO

14.93

5.59% 0.79

Dopo l'orario di chiusura: 15.74 0.81 +5.43%

Neogenomics Inc (NEO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché NEO Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$14.14

Aprire:

$13.55

Volume 24 ore:

1.53M

Relative Volume:

2.38

Capitalizzazione di mercato:

$1.77B

Reddito:

$628.25M

Utile/perdita netta:

$-78.55M

Rapporto P/E:

-19.39

EPS:

-0.77

Flusso di cassa netto:

$-29.73M

1 W Prestazione:

+10.43%

1M Prestazione:

+7.10%

6M Prestazione:

-2.42%

1 anno Prestazione:

-2.23%

Intervallo 1D:

$13.35

$15.08

Intervallo di 1 settimana:

$13.21

$15.08

Portata 52W:

$12.77

$21.22

Neogenomics Inc Stock (NEO) Company Profile

Nome

Neogenomics Inc

Settore

Healthcare (1181)

Industria

Diagnostics & Research (57)

Telefono

(239) 768-0600

Indirizzo

9490 NEOGENOMICS WAY, FORT MYERS, FL

Dipendente

2,100

Cinguettio

@NeoGenomics

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

NEO's Discussions on Twitter

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-05-01	Ripresa	Craig Hallum	Buy
2023-12-29	Reiterato	BTIG Research	Buy
2023-08-21	Aggiornamento	Stephens	Equal-Weight → Overweight
2023-05-16	Downgrade	Raymond James	Outperform → Mkt Perform
2023-05-09	Aggiornamento	BTIG Research	Neutral → Buy
2023-02-24	Aggiornamento	The Benchmark Company	Hold → Buy
2023-02-01	Aggiornamento	Needham	Hold → Buy
2022-08-26	Downgrade	The Benchmark Company	Buy → Hold
2022-08-22	Downgrade	Needham	Buy → Hold
2022-06-03	Iniziato	Piper Sandler	Overweight
2022-03-29	Downgrade	BofA Securities	Buy → Neutral
2022-03-29	Downgrade	Stephens	Overweight → Equal-Weight
2022-01-18	Ripresa	Stephens	Overweight
2021-12-16	Iniziato	Cowen	Outperform
2021-11-05	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-10-14	Aggiornamento	Raymond James	Mkt Perform → Outperform
2021-06-03	Iniziato	Goldman	Buy
2021-02-25	Ripresa	Needham	Buy
2021-02-25	Downgrade	Raymond James	Outperform → Mkt Perform
2021-01-28	Iniziato	Truist	Buy
2020-12-11	Ripresa	BTIG Research	Buy
2020-10-28	Reiterato	Needham	Buy
2020-09-09	Iniziato	Morgan Stanley	Overweight
2020-08-28	Iniziato	Guggenheim	Buy
2020-07-29	Reiterato	Needham	Buy
2020-06-25	Iniziato	BofA/Merrill	Buy
2020-04-21	Ripresa	Stephens	Overweight
2020-03-02	Ripresa	Craig Hallum	Buy
2020-02-28	Aggiornamento	First Analysis Sec	Outperform → Strong Buy
2020-01-23	Downgrade	First Analysis Sec	Strong Buy → Outperform
2019-10-30	Reiterato	Needham	Buy
2019-05-01	Reiterato	Needham	Buy
2019-03-29	Reiterato	Needham	Buy
2019-01-03	Iniziato	Needham	Buy
2018-10-24	Aggiornamento	First Analysis Sec	Outperform → Strong Buy
2018-08-21	Iniziato	Leerink Partners	Outperform
2018-05-02	Downgrade	First Analysis Sec	Overweight → Equal-Weight
2017-09-11	Downgrade	BTIG Research	Buy → Neutral
2017-08-24	Iniziato	Gabelli & Co	Buy
2016-12-15	Iniziato	Cantor Fitzgerald	Overweight

Mostra tutto

Neogenomics Inc Borsa (NEO) Ultime notizie

10:43 AM

NeoGenomics: Q3 Earnings Snapshot - The Washington Post

10:43 AM

10:00 AM

NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

10:00 AM

07:00 AM

NeoGenomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

07:00 AM

05:42 AM

NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

05:42 AM

Nov 03, 2024

Emerald Mutual Fund Advisers Trust Sells 314,330 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat

Nov 03, 2024

Allspring Global Investments Holdings LLC Reduces Stake in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Nov 03, 2024

Nov 02, 2024

Blue Trust Inc. Boosts Stake in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Nov 02, 2024

Oct 29, 2024

NeoGenomics (NEO) to Release Earnings on Tuesday - MarketBeat

Oct 29, 2024

Oct 23, 2024

NeoGenomics gains conditional approval for solid tumour assays in New York - Medical Device Network

Oct 23, 2024

Oct 22, 2024

NeoGenomics NGS tests gain New York State approval - Investing.com

Oct 22, 2024

NEONeoGenomics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 22, 2024

NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test - Business Wire

Oct 22, 2024

Oct 17, 2024

Truist Financial Corp Sells 4,699 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Oct 17, 2024

Oct 16, 2024

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 - BioSpace

Oct 15, 2024

Analytical Lens: Exploring Neogenomics Inc. (NEO)’s Financial Story Through Ratios - The Dwinnex

Oct 15, 2024

Oct 14, 2024

Check out these key findings about Neogenomics Inc. (NEO) - SETE News

Oct 14, 2024

Oct 13, 2024

Renaissance Technologies LLC Cuts Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat

Oct 13, 2024

Oct 12, 2024

(NEO) Technical Data - Stock Traders Daily

Oct 12, 2024

Oct 11, 2024

Breast Cancer Liquid Biopsy Market is expected to Double Its Size - openPR

Oct 11, 2024

NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 11, 2024

Oct 09, 2024

NEO (Neogenomics Inc.) may reap gains as insiders became active recently - Knox Daily

Oct 09, 2024